KIN - Kindred Biosciences, Inc.
| Previous Close | 6.89 |
| Open | 6.86 |
| Bid | 6.71 x 1000 |
| Ask | 6.72 x 900 |
| Day's Range | 6.70 - 6.88 |
| 52 Week Range | 6.62 - 15.75 |
| Volume | 112,170 |
| Avg. Volume | 165,111 |
| Market Cap | 261.724M |
| Beta (3Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.67 |
| Earnings Date | Aug 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.81 |
- PR Newswire•2 days ago
Kindred Biosciences to Announce Second Quarter 2019 Financial Results
SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2019 financial results on August 1, 2019, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
- Insider Monkey•20 days ago
Here’s What Hedge Funds Think About Kindred Biosciences Inc (KIN)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
- TheStreet.com•27 days ago
A Handful of Small Biotechs That Make for Merger Chatter
The biotech sector continues to have a very good week, although some profit taking did take place in the second half of trading Thursday even as the S&P 500 hit an all-time high. On Wednesday we considered a couple mid-cap biotech names that would make logical buyout candidates should we see an uptick in merger-and-acquisition (M&A) activity in the second half of the year. Kindred has just one approved product but several in development.
- PR Newswire•2 months ago
Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational
SAN FRANCISCO , May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in ...
Motley Fool•2 months agoKindred Biosciences (KIN) Q1 2019 Earnings Call Transcript
KIN earnings call for the period ending March 31, 2019.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of KIN earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Kindred Biosciences Inc Earnings Call
- Zacks•2 months ago
Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Kindred Bio: 1Q Earnings Snapshot
On a per-share basis, the Burlingame, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $515,000 in the period. Kindred Bio shares have dropped 18% ...
- PR Newswire•2 months ago
Kindred Biosciences Announces First Quarter 2019 Financial Results
SAN FRANCISCO, May 9, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs. For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share. While net product revenues were lower versus the fourth quarter, sales of Mirataz from distributors to veterinary clinics increased quarter-over-quarter.
- Simply Wall St.•2 months ago
Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Kindred Biosciences, Inc. (NASDAQ:KIN) have power over the company...
- PR Newswire•3 months ago
Kindred Biosciences to Announce First Quarter 2019 Financial Results
SAN FRANCISCO, April 25, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2019 financial results on May 9, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of KIN earnings conference call or presentation 6-Mar-19 9:30pm GMT
Q4 2018 Kindred Biosciences Inc Earnings Call
- Simply Wall St.•4 months ago
Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals
Kindred Biosciences, Inc. (NASDAQ:KIN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
Motley Fool•4 months agoKindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript
KIN earnings call for the period ending December 31, 2018.
- PR Newswire•4 months ago
Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 million and a net loss of $15.4 million, or $0.46 per share. For the full year 2018, net product revenues were $2.0 million and the net loss was $49.7 million, or $1.60 per share.
- PR Newswire•5 months ago
Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 SAN FRANCISCO , Feb. 19, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
- PR Newswire•5 months ago
Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference
SAN FRANCISCO , Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...
- PR Newswire•5 months ago
Kindred Group plc - Year end report January - December 2018 (Unaudited)
Underlying EBITDA for the fourth quarter of 2018 was GBP 58.8 (74.5) million, and GBP 203.7 (185.0) million for the full year 2018. Profit before tax for the fourth quarter of 2018 amounted to GBP 45.0 (55.9) million, and GBP 149.5 (132.0) million for the full year 2018.
- PR Newswire•6 months ago
Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Jan. 23, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional shares of KindredBio's common stock, at $9.50 per share, less underwriting discounts and commissions. Barclays Capital Inc. and Stifel acted as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.
- PR Newswire•6 months ago
Kindred Biosciences Named Best Company in North America by Leading Industry Publication
SAN FRANCISCO, Jan. 22, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio's transition to a commercial-stage firm in 2018 with the approval of Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.
- PR Newswire•6 months ago
Kindred Biosciences Announces Pricing of Public Offering
SAN FRANCISCO, Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $40,042,500 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 632,250 shares of its common stock on the same terms and conditions. Barclays Capital Inc. and Stifel are acting as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.
- PR Newswire•6 months ago
Kindred Biosciences Announces Proposed Public Offering of Common Stock
SAN FRANCISCO, Jan. 17, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions.
- PR Newswire•6 months ago
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital
SAN FRANCISCO, Jan. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In the study, which enrolled 23 cats with anemia, epoCat rapidly increased mean hematocrit (a measure of red blood cell count), with statistically significant improvement seen as early as Week 1 (p
- Yahoo Finance Video•6 months ago
Bringing world class medication to animals
KindredBio is a company focused on bringing ground-breaking human products and innovative new technologies to veterinary medicine. Yahoo Finance's Adam Shapiro and Brian Sozzi discuss with company founder & CEO, Richard Chin, along with its founder and president, Denise Bevers.
